

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **September 14, 2016**

Commission File Number: **0-24260**



Amedisys, Inc.

(Exact name of registrant as specified in charter)

Delaware
(State or other jurisdiction
of incorporation or organization)

11-3131700
(IRS Employer
Identification No.)

3854 American Way, Suite A, Baton Rouge, LA 70816
(Address of principal executive offices, including zip code)

(225) 292-2031 or (800) 467-2662
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ([see](#) General Instruction A.2 below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 7.01. Regulation FD Disclosure.

On September 14, 2016, Amedisys, Inc. (the "Company") issued a press release announcing the appointment of Susan Sender, RN, BSN, CHCE, as Senior Vice President and Chief Clinical Officer, a copy of which is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

The information included in this Current Report on Form 8-K under this Item 7.01 (including Exhibit 99.1 hereto) is being "furnished" and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of Section 18, nor shall it be incorporated by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. The information included in this Current Report on Form 8-K under this Item 7.01 (including Exhibit 99.1 hereto) will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

<u>Exhibit Number</u>	<u>Description</u>
99.1	Press Release dated September 14, 2016

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AMEDISYS, INC.

By: /s/ Paul B. Kusserow
Paul B. Kusserow
President and Chief Executive Officer

DATE: September 14, 2016

EXHIBIT INDEX

Exhibit Number	Description
99.1	Press Release dated September 14, 2016
EX-99.1 2 d431261dex991.htm EX-99.1	

Exhibit 99.1



Media Contact:
Kendra Kimmons
Marketing & Communications
225-299-3720
kendra.kimmons@amedisys.com

Amedisys Welcomes Susan Sender as New Chief Clinical Officer

BATON ROUGE, La., September 14, 2016 (GLOBE NEWSWIRE) – Susan Sender, RN, BSN, CHCE, has joined Amedisys, Inc. (NASDAQ:AMED), as Senior Vice President and Chief Clinical Officer.

In her new role, Sender will oversee clinical practice and quality, set and maintain clinical operations standards and develop and implement clinical programs and clinical education. She will also be responsible for every aspect of patient care and quality outcomes and support clinicians across the organization.

Sender brings more than 30 years of experience and expertise in the provision of healthcare at home. Most recently, she served as Senior Vice President and Chief Clinical Officer at Kindred at Home for three years, overseeing more than 35,000 nurses, therapists, social workers and aides across 40 states. She was responsible for clinical program development, policy development, quality and performance improvement, regulatory compliance, clinical analytics, and clinical education.

For the five years prior to Kindred, Sender held Chief Clinical Officer and Vice President of Pediatric Operations positions for Loving Care Agency, a regional provider of home health services in New Jersey. Her experience in clinical management also encompasses 23 years at Gentiva, the last seven as Vice President and Chief Nursing Executive.

She specializes in improving quality, clinical practice, developing policy, reducing unnecessary hospitalizations, and in the clinical aspects of Mergers and Acquisitions. She has served on national advisory boards and panels for the U.S. Centers for Medicare & Medicaid Services (CMS) and The National Quality Forum. She holds a BSN from Adelphi University in Garden City, New York.

“Susan is a proven leader in her field and an exceptional individual with a powerful voice for inspiring her teams to perform at ambitious new heights and an unparalleled drive for setting the highest standards for evidence-based patient care,” said Paul Kusserow, President and Chief Executive Officer of Amedisys. “I’m confident that her efforts to build trust across disciplines and distinguish our clinical efforts will establish programs that translate into superior patient care.”

“I’m excited to join a company that’s committed to staying at the forefront in the home health and hospice industries,” Sender said. “We will continue to focus on clinical distinction in the communities we serve and cultivate a culture of productive collaboration to make sure our patients always remain the number-one priority.”

About Amedisys

Amedisys, Inc. is a leading healthcare at home Company delivering personalized home health, hospice and personal care. Amedisys is focused on delivering the care that is best for our patients, whether that is home-based personal care; recovery and rehabilitation after an operation or injury; care focused on empowering them to manage a chronic disease; or hospice care at the end of life. More than 2,200 hospitals and 61,900 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, TN, Amedisys is a publicly held company. With more than 16,000 employees, in 421 care centers in 34 states, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 340,000 patients in need every year. For more information about the Company, please visit: www.amedisys.com.

#

GRAPHIC 3 g431261g27s77.jpg GRAPHIC begin 644 g431261g27s77.jpg M_JC_X 02D9)1@ ! 0\$ 8 !@ #_VP!# H'!P@'!
@H(" @+"@H+#A@0#@T- M#AT5%A\$8(Q\E)"(?B\$F*\$S7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM
[BYNL+#Q,7& MQ(C)RM+3U-76U]C9VN^BX^3EYN?HZ>KQ(O/T)?;W^/GZ_\0 'PS PS! 0\$! M 0\$! 0 \$" P0%!@<
("0H+_0 M1\$ @\$"! 0#! \$X%=%*CSJ]9C4J\KL?3%Q<0 M6D+37\$T<,:L\C!0/Q-<^WC2UNI##H=C=:Q(#@M FV(?
61N/RK!\\$>+;Q!H MEMJVNRW.HN"4AAN)"8D53@87OT[UZ!%%!&L4,:QQJ,!4& /PK-J,7;?S:-_P"\$6T+JFE6]9
8EV\UQ6M11S/N/E1B MR:)=V@WZ1JD\+#I!SN[8VE_:X\Z\$G((.<.A[J<' MZ=ZU*Y+QS>/H7V#Q%#G=:NT,BC^-7H?
HRJ::]YV)?NZG6T44C,%4LQ"@#) M[5!9C>* _D/AC1GO7422L0D,1.-[?X Y^R>*-,N,X"W*
M9/L3@_SKKC2CRN^YS2J/F5MCZ(HIK.J*6=@JCY2< 5D7OB_P]I\OWSV M6GW+O,JE@'C*[@.I&:*^PN9&]
16+K?B[1?#S"/4+P+,1D0H-SX]<#I^6=% MUW3_!!8_-;F,D88JP(P5/H11RNU[#NKV-&BLW5_\$.DZ%&U*^B@)
&50G+- M]%'8]G]2/#5Y>I:KU"C)JZOG)+2YU55=2N;BTL9)[2S M:|F7&R!7"ECGU/2K+,J*68A5')). *Y^]
>>&+&0QRZO"S@X(BR^/Q Q0DWL M@;2.,O\ XKZQ:7,J^BV]O-\$2A620L4;W]:EB^5[IWAZ 72B^U>)\DC4)M2 M-
"<+G'4<>U<-J\$K>(/%,\D.2;ZZ(3Z,V!^E>G:/17AW0]4DU'5=3L3?#"0 M1O,N+=%&U0!G
[V ,FNJ4812T.>,I2>Y3TCP3JGB2X75O&-S*X;F.S#;=H]?\ M='L.?6IO^%0:3]M\S^T+K[/G/DX&<>FZNKTGQ)
I6MFZ.GW/FI:,!)(5(7D9R M">HX-4+GQ_X9MI6B_M\$3,OWO(C:0#\0,5ESU+Z&O+"VIO6EI!86D5I:Q+%#" MH5\$7H
*FK)TWQ1H>KQ/+9:E ZQC+AFV%1[@XJ'^\;>&]/A:275K>3;QLA?S& M/X"LN63>Q=U8W:*HWF M:=I^F+J-
Y=)!;,H96?@G(R !U)]JHZ+XPT77Q/]BN M2/LZ[I!*NS"_WN>U*]7L/F5[&Y17-3_!"\,02,G]H^;L^T,3.H_#%7(?
M\$VFZII=S=:1>Q7#0H20.J>Y!YQ1R2["YEW-FN^ B5"]_H5OI<&#/=W("#_ = M5F^/JKVNJ:E'K=U&S2F.!GV2/NQ-
M95 Y)#9WH!CBMN,QZKXM>4#='S1B5 MNQEDP6_[Y50/^!5:7*[DM/RL;M<"3_\$W]FZ8-'M9-MS>+^(/*1]_SZ?3-
= M=K.KVNAZ7-J%X^V.(<#NY[*./>R";O(J)-#]5>#=%,KI,=^Q)B(E?[._SNPY/3_(KRE\J59\$/W&# M_0U]*?8[7_GVA_
[]BOG?7(5M)>U"%1A4N9%]MQKHHR3;L854TD?0\$MK9ZYI M*17D*SV]PBNR'HW0CI7@6IV=K_PDMU9V>(K;
[4T<>3PJL=?:O7M%U^.#X9Q M:HSY-M:%3_OK\H'YXKRCPOI+>(?\$UK9RY9))#).?JD-RY"AW]V/TK \!/<0ZO+)8
(LE^?DV MJMT5FZN?JE5!Y"NM^+FHK;Z78Z3\$00FOYC*.RJ, ?F?TH^\$>C+%876M2J-\ MS>3\$3V4?>/XG^5-
2M2;8FKU+(XWQSH[6B:XMO]NFO;F2(2W,LN,ER3T]L5TF M@ZN?!GPX^W !KS4IV-LC=!.CYXDF(3_='_059]3
M:Q :BZ9%:R6UI:VBQP+)_V9OQ(_2M.5M),BZ3;1/X8GL+_ ,3'4_\$U&CB M!E;S:==^-?%3ZQ]D?3]&MPNZXF39^
[3DG',-433K\$O'9/((X(%./,). 6]?IVKM=9T_2_@&:*&%"KJ6 M/R?-9 6DD8\H+82?NN3W,KX;:0FJ^*EY-\%
M\$TCCUR- MH'Z_I57QW8Z9IWBjXL]+MU@AB10R DC?C)Z_45I_#K6VTN:ZAMK3SIYBKRR/ MPD4" ER??TKD
[^?4=1N+V8DM<2M(WXG-)/VC9#MR)'6ZA#<:)+["./,9U M:X,DY'4KCY5/M@"I/AQXJTS0GN+4D\$273 BYVY
XQM;VKH-(UW2_'DWAf7 M3_L(K93;ESB7*X&1V&17">+?"=SX5U!89)!;S F&4#!('4\$=B*A6E>\$MRW
M=6E'8]"LOASI=SJNK7%Y;126-TRM9&.0_(",DC'N>*FU&S;3M0N;)^6MY6C M)]<'>O_IGNIO";+S-
'%.RPENRX']LYKS7QK'L\9ZJH&,W!Y@&BG)[MBV%1+E31Z[J5II5UX/AO-6M8IX[:R\$BF0?=.SM[UXLUI>6>A)
>='!J\$C1#M MO5,\$_AD_I7INO-/X@;3O!NGN5588Y-1E'2) !A?J?3Z5::'2-?OK_P %2VT<
M=KIL,9MGC;YU;)'N,C\SFLX2Y%_6Q@_3FNR\)>\$TT+4=7N?*B\JZEQ;%6W?N>N/S/Z5Y1XI\,77A?4Q:7\$B
MS1R+OAE7C>N<;!X5?8<] !3JQTYH] M14WK:70W-7%OI@A@T^\$RZC<-MLX'=F2,]WVDX"J.?TK4TC3())
TZ.TC8NPRT MDC?>D<[LQ]R:JZ-I4T\$LFi:DZRZEGUKD5^\$NC,KM<7U]-,YR92Z M@Y[G&.: [NBB,Y1V!Q3W.%
B^&8BL)-,3Q!>#3IG#R6_EKR1Z'MT'Y5K'^? ^D M^&;[IJS,\D[IL+S.#@9SP /:NCHH=235KB4(HP-3
&:/K6JG4=3CDN7"!\$C9 MR\$0#T]ZUK73[2PL18VD"P6ZJ0]P!GK5FBDY-JQ5D>=:(K2'43-'Z@US; M*V5A5-
I8>C^/JW/%7@2Q\26]NLU39\$Z)E=G]TKZ5U-%4ZDV[W]G%* MUCS2P^\$4D,A^TZ[(VX9;9"A8>A)]*V]
5^&^DW>@1Z9IX%D\4GF+-MWLYQ@ M[NYKL**5FW>XE3BE:QY[HWPEL;2X6?5;PWP4Y*\$IL0_7G)K9
>9>"U\46UG' M!+=9M:\$A1Y>5VD#C QCH*ZFBCVDF[W'R12L@'I6#HWPDM+2\\$/^J7QO8T.5A1-BM_O<_2O1***
4DKZ[AR1['%:G\ M ^N?VUHfIOIMWNW;?+#)G&.!Q@>W2H[SX?W^OWL5QXCUXW20C"Q6\ C&._/;
M/TKN:\Y\8>.]1T#QE!:*F+!'5>5 !NG!'/)YBJA*(S97?B/X@7]OIJ>;)R@0(JYM%N)=N64Q)"!O1<=M65PW<;:4\$)/6)
F?*"M656[(:)!BQTAA*\$*]X#. M>GA3%H^EH,.O^Z]*1F?&FMEAIY2PZH)SA(X'4\$T[LY#MPET]1,=?EI3NRB M]
<Zi6%H1"4ZTFS?;>80I*VU]7%,I;5G:(LFUY@KU4=PJPMUN./JZK*B<] MYSW=AI3+B;A+S2@A.'
9B/#*F;.+A=Q*94=4Z1_;VT\$A PCOG/"B"4I3,\$&2:AQ.AG6O>&,649_2@A84DXLDP"/#K%+ M3B*2DQAH)<^,^5%
+L:B31 M6RUA;3NZJ\$ZT\$N.9N=!'P#_8]>(&5 81"<@.73DRK*O3DRY%/I;.,2@#>1T? M,4+FW5H\C\0%*N

[=&KX\,_E7M.+^2RMP\3T4^9^E!#RQ[Q8;!OZTAI#8A(\ M=_G]K B(RHV[!U8;/>A/TH--)ZK:4]R0/L#_Q ! \$! P(#! 8%! PT! M ! @,1 02(3\$%\$T%1(F%Q@9&A%#)"4MS0,#-BL<'A("D4W*"DI.BLM/P M\<+_V@ (0(3\!';)R2DJ/(:UTL6#F=!

Q[Z%J\,W"ED?7R\,E7E4,)U M6I<>Z,/FJ?LK%?:JWOXT?XZAI9AM11RQ_\$ #RH@I)2H01*BD8

\$7*\B,036U;E+;V"U*<1' M36D#% V8N%3B.)69/\$YFM*[JRRZJ=SM[99]8(Q)/,)*0&=+8>;*4J;*5*\$@\$9&M+MWVE

M)0MI25+J41K3EN^P\$EYLMXM*;MKA[Z-E13STK<+#!<>3T\$JPX@CG'72VKIQU>)"E"/"N9T//W:7:W36\$

MJ94D*XZSU2*4P^A.-;2D()@\$BE6MRC=XF5#>>KEKV4JTND@DL*RUZNWE\CQP MAIF9W0S_ &E9D=VDT9

0EFLUI=<+5U=IRA.+^B=-1&ME;KT13;2U.(14) M4G#J.TS6RD.)V@I""0E)5BCDG3\<>+FUD-M\$8SDI7)

(SP;/6R2ZVSV MLD \.GE6SG&;E% TTX2AZY4HGWL"M(!5QZ5LS=,AP[DN!:3_P"2#6VB56K! M1,J<3

^LH35M=MM.6]F^K&4H 4X?9;4Z4&0G+!^]-7URBYN%.H"D!0&1(RC@F. M%6>TVK)G=I;4K&K\$22-W3Z4IQQ'YF

(PB,7//G5S?6A=-Q;,'? MVU&1/.)Y]M/;6ZR&BPKD,\$D" G2!3.U76+53"4RM1)Q'KIK:Z6;5#:6RMY,

MR51AD\>=.WUN\];W2T.(>:C&\$884!RY=]7M\N_3D0VG) K:5TTPBV2GIW+0 M24C@DX8E0YCA2'[XOK&I>.,)

C%/?YU1*0>/Q\XK\$QT>A\$3]@C[Z24!2SAR@@# MMTI19.(1&0 \C1+0]4<(_A2EHPJ&\$=(S)P\IFD84H

(.F4 :_*66@HX4#/ M3J_&I:G3++\>Z@6<*_5*YUSC_13;MNU=-J4;,*#TAS_YUT_Z#B7X)

R_JK>6K/T36_6;LXI7:HGVC_Q_ \$" @ \$"! , \$ M!P0(!P ! @,,\$\$042 !,A,10B02,R45(&\$!4D8G&!,,\$)A/9T*5(?[;:Q)

^L5./:_-QUNZ/^7V7> M_P!WVO\ _/&^W3CM1#WY--+F5%^;P4WF[S%8=#@>O"QQHL:*,*B*\$11%\ M5>@']

#7*L?2 C3]16,=HY[PMQV=H]-[TUD/XI&/K]5C4) _REVPPCW[%F3RP M0(/5F?'Z9/IQ2GU=SXXZCI]VT-

QVIXWE,8>FR*79CTV8XW6)X8\$^::5(E_U M8SXV# M;UR>)DTV_7N-7QSA"V2F(!ZCJIP>HR.5?U.K6EQGE-)

NE ^+1QAF0?F!P- M2%VM]GE=XMF9%@QV]\GOD\$8[YZ<&WI]72F! MCJ\$,L4\$G+8HRPH>LIW]@<2+6U.H

[0#,J&41/&OQ9)=I"]NN.&J5K]2Q82\$ MV'B@F24K" '&'F1BA(R1Z^O%.J*#5*4CTEYK\$R

[88P=I=I#Y=@;ID\$\P0ZM3 M:68[85YFT3-G&(GO[W\$=O4:M>G9EIUY%2K9-I&#N MBOS&BC(?*8QM)!Q!

=FAAEL6A1%&5E5I(C8Y=B4Q-W7V4;9XLWKN]*P,K:~6W MF,6M2GF\$"WYMA]JL:JJ1(W3V88U:_J <4 \[P0+

(T0U#4"\$K59)2A!>O M!)M"Q]F?>S>Z.-3U6!@FH:K9CTF@>FZ*.NAFN6@OX3*BC\6.+TL*4H6U\R+9

MUJ_.UE*" ,4D2*N(O?9UE)=Y1G(/H,;]&*&TTKZ)I]B5%&<<^.%GEO7G5>G, MG8.%^560#^F:34,<6G5,5:Q!5

(>8)PK33+Z+#'R^4K=O8R>G&CT]'BKLPI0 M(UF% &LFR?3M)K4:E29<6*L%VD?O,-A0<1RO M8RQ#8SN^*]

+^HW**)J2Z>FG7*S*CPJS&1X;]:3&_F=UR>J[,=>YU1)MO*BTN MTD^_&S8EF\$.7]-N <:\GK^EUQ'6MW3)

7TRLHCE;0X,QK?%1,\$PM81&Z#7&B M_1W5ZZ+/I5B&SI=F)\$V6/ HQ)\80CR%D&25][E^A[OI59B

(5Z:M90XY<1Z^ MB; BIE_]G&2?>=>%1 %1%"HJC"JJC"J'Z <-2TZ]5TZ">\$I/,B)=:E0T[E

[Q%"KR6###RHO>;:G>1CT;J>*7T>TB>.:<-4T2I-I%W2]0:PT+7_ M !*SU/\$C:^Z-(W6<@88>8>89]

>+ :QXBQ/B6W9*\N,+^IVI&N>D:@N- M5LG=!HEQWALS]5DNP^*Y[4JQ](I,07'[H*#JQQ!K.CV*)BTY=,;2

[:R00K M61N8.3-71MOG 897ICX<6]7CL5N8]@M;T^,C3J#S92:+3FE'WZZ\$++S-O*B M+%O._E"5ZZ;

(TSZEF9B]S9 M#&"&_%TXL"-WC3\$D<1WPF,(TL*UG@7!*O%7\$K.9/>?IU))0L\DA9HL!WB:58

M_\$\$SF18F\@#^&\,ENOF/?BK)O;"6J;%C:H.(6YKMR[X]9T4%<_O'BMF7R>U MGL%=F'G>Q)

8Y?/Y8S#RT&P,%Q]!P#:&-MM["1Q28]M(K'&&!^,6)%2*%0]T+3P+!>PXJE'G6JL0>19##+,TNZ0RQ3GF

>9>6J%= MP'7BY4@LM5U2.:18;+R>94EH<DO\$,>3=LW].W\$6G?2/4Z_@8XQ%)!0YG MC+T2]!%

XGXWVK\6XW:K M]QH'MI%:7,LX_P 3N)W7XP087YG?MPD42+"&H5\$10B(HZ!55>B@?LNG?CE: MU#-

IW7"7.3+/ILP]&2W\$C_&Z+6=,Q(6DF;^9C^U*D @]P1D\QONET?2Y&^:3 M3ZCM_JT7'W:E4K_]O#%_L0?

L/_\$ "(00\$ @(" @,! 0 \$1 "\$Q M05%A\$!"Q@9"!L?_: @! 0 !/R%9ERY3Y+ M:8I4!F>JLCS%/& [U)A?:-

ZO\YR@^K?JA?S_!B#8T:G*THV^7#.=OT0*]@(M0@ '\$X1" W%BI@5>R?>EU+|O2R*7;G%

XB>D\$0 ;^\$<,5W'AIQ"\>0HUVSKSA#:G.);3&K!DY+7)"\$J#5B4'&;U M5"Y> [\I/RIS%Y4YPZQJ"&(W!

H";% !:A28%1%Q.M[MS@U9@8Y_D5!3>] % MJ0\$0C.;8?"8Z-<-K-#2,H4';EPN0N<6O7LM8H"L VKH

W5Z#"J"7K5C%X7[& M[^ 3 N]>Y;DYN62B=(U=E 74U;EF!MSA#9H).APY2IB_D-L<1@Y:"-Z#=(E M:1,

[/S.TZ5M#2?;,J G5A*(J+2%L-=Z7[S>3%ZTN";,YD=-=BH)@_F"*T' M;6T*HSE^6>^A\$;QJNC#938BW2%!

21<3"15M]J[>U+A&>T1CV'R,(XBD&P4 M_&B&:#<.D(C!28[L\$MLF\$VN- PEH4 >,VZF/:'ETT-3#)0J2+VNS']!)

IV0 M6Y<0PT)7*+!<=B+Z9\$OLO%/E"2&UYH>M9L05)H>9(D*:<S;(/?NS#5A\$,, MXL\$&DG=OS,(KD@@:P#

UX:>KVW8/JN';O3R"K3! @T(8/2#.D!F@2BSO^QG M8A)!_4O&Y:P@:2E\$!*U=4&=MQHR'HR(<1.HPH?:PC

MZ-)WL8&1?DC&*8(6)I YU[(ECY")0E0SW.9P&FW6"-.,AXAM#J9[KHRQT= / M8W%><['=J/J.119I"M3)

@7=:A#EPAA[7A, &4&(J!'H@> [Z;!(GX#VAFW M=!\9)#;M+82X#AQXN+ 6@ GR_P 9/F9Q]55!#%

#TIV7WC^2:-A0(ARYZIW M16T&'L2?PQBEYN^JQ^3#\$(F4T_] KD?0<:6<34R9#)J0/ : P# 0 "\$,0

0DDDDDD:] M<@U !\$!G_DY-#;3U ^M(V40\ 2ST#V(%G0P*4!.PC6V !M+L7:AX))) M&I))/_ "\$40 0\$ @ \$"!P\$!

0\$ \$1 "\$Q05%A<8&1H<'1+\$@X?_: M @! 0 !/Q!%"<9?8^?W+['S^Y?8^?W+['S^Y?8^?W+['S^Y?8^?W+['S^Y?

M8^?W+.AKZ]9)L64\$^ MV8[7;):B\$,?'#0ATUT)7" G4>6SA M4'G)-]L-.NCRF:4#Q]&];AB#1+!GB@A9C>%8

(YGE]N<>GQ@54("62R0 +&R M;SAG\$Z<?.7_]Q28.^WPL&[T\$(B\Y)CZZ *#9 UT2I,O^+Q%&BR\$'B0K.,EY

M"8X21Q' <0. /]!#M@ 3^UG'IKVR3JG7M)/_ #%+V>2A\$D]01&-1X'^+BK: MJK"4KL!4['@IT9"V*B]Q;"7@6

[\$5*12FA_W-F*88 K'3)37#->9?I41;+0 M8#YS;9;'(P 3!ZR%-(B00WPWO+IK?%8"6Q=JRY!1.FO*2[,97'O#MZ

((QKA)RXYD3WJ\$! M600)8) >0@ LO%;;\$9="&X+L68(D)T?\ M5,XAS=BTV0VR;RQJ> WCUKL"6-

&!/:0U*YR VX4CX-.[*^C4I-V\$^%G\$ 4'R MG0S2CJ8@GCL0NEL&H&^K7+2/VK)&G0 MT "90]X?CI]
@4C,R7/4K4I9[2Q-X)WND0/RUU8"X(I?"8;EQBX%<-UURUH M#-4S8KG(CW50A)2URP5H=8;.,57L&.=:\$S\$-?
JF2"9/8 29-AJ]+Y@6WIV9- M1E4 -9:I_P C^6D:H!BSY=R-HZ*/56N F#(BG%/F(+LW\ M& "657=T'S1K'@9!
#3"2NK5/MS2G0K7*PR+JE93B\AX8PC/E!Z@ &?8:%LTL M5%V6#VP;XS!SQI-G=)4 &9#IWF*L])1)ZAF"#P
((=<123EG.+RIPPSDB!E^ MG%VDGED#4])QI9QZ?61U#7A(C;YW . \$#IDGA_/Z^^'B@G\$A@HA"D4 MI2W
(Y,D,B5'K*("8SB6\$8&M!S44.V)B=0098FEN"GIF][*U!M:-#MC>!B)RU M@5Y[CJU-#!H?
&FGWD.QKXF0.@3P"3([&O U MD'0/0.,AV/8R'8]C(=CV,AV/8QN)GU2*)1J(F+')5\$K55[=VYP+X:IX-*.DQ
M#R#Y@Y#4 .D"0AKR)D'0)X!)D.Q[&0['L9#L>Q@!P3RUQ@#_Q F\$ \$ @(' M @(' @,! !\$2\$,4%187&!D:&Q
(\$0T? P_JH " \$# \$_\$\ RU\< M8E#/J0/VU\8@@2&KD^R ^LL#302 I%P(<#6D4I_!8 \\$_ T9\$2/+;\$;N0T=X< M632?
KPG/^%)&8X-XGLN);>3ZU@&E(2YK^&L.!%!.+UW_ ,^1B%,#T\E,^L M\$#%P[6=N>+Q&F#;\$=(CX'N., #H5?
1BO=.MY'\+:1,DP?'AC ((E;_ 'BS*H0(HR'=. *K#S-42Z?TUC,DD6@%H8"#64%7=%@0V\$7SSQ6&Y;%Y MA
(E03^[O\$@ "0\$.2.,V:33*@\$) ,V3AHL8B6IX#U\1BGJR: D#C0\$^##H MC TYAX-"&SUI+0T"AY0?)
OYEPZ4;.YVKY9MPKQ&L-JH >6)=:0]XE AHDFB" MG"0^5:P*23L1%O1.HP[0?L:P-R^(REI'MDKBHP
(DBD/D\ :_6\$Y107"EKN# *J WXJ))&3O!-AB!=I7C]8I/=31X4E M)*HQ:#NG <\$&'CK 4!4!PK15:M)
Y;Q1A6S\$#&XG]A+ MR"'SV]:O_6%HR1F>HF3[C(8SM6ZN5(_AKQG] M?Q42"J1*^M8G+!RC]XXWM?
T09KQ_C^LUXC^_0 *! ! 0 " @(' 00!!0 M 1\$A,0!!46%Q@9\$@H<'PL1 PT>'Q_JH " \$" \$_\$\ :U]<]&CFT<"
M#1B\$40@!Y^/ !>,-^:1H:XIQR!@> 6]4 !R3^#^R<&X'1#?!,?#*JG'X;8 M_M]3_JD?],V&,?OU_/#K'8'TSKKE%
Q_-/\ '-?HUKDU65&9"']7QS948%20+ M5*R=Y, LGQ#4*FAMQPT=V9+B%0"Z;>^*1':1^2O?"]E#SGF#H?7\$61Y
8U\ M?WZX8!64[(/@,;UZX8#HW_ '*^4?FOQXT>^1X F]V>DLM]ZX]?\$?, =Z@J)'0.-Y)COB[/:1\"PV;!FAZG(:H)
@.5T\$^@P:X2D^(2NA2W MJ5WCAJL,#,LB#>I/SKF %>DH2D%6S%G_ #%K- "GR!4!EH\&O9?C/ M&VI.\$D=]
MAY)HY#)@Z>707KKS<),';1"W(#)(JA'92N"24Z!M^>)1](PM@D MD4'[<0SBHUJ X*%
(.@U."0D*+RAZ,!'@ &KQ%5-1@I'D7))A,\A?8O>9(Y@T& M^.^2H\$DW",E>Q*U QS*8[>!,K)*AW!
+P\48Q@BXAB.@F37@C%\$D5LB> \$I^+ MP(P8.P*- FM05T:XO0':D0-RCKOURF\$PT>D*8=!. "<=L7 7V\$*>]
I;NK6^_,JEB*22 KFZ];YH7(8Y.H"8O:N.TOGTB R%(MIG?;PQR,3DWA4R+XYE2<'A%.=Q#0#O'%)HH,CX(26]
YO*0X^X1%X%C,36KP M%^2# 8@HP0B7] \>%I'46YR77B8YVGAKIM);XS!!T!RN8#J)6!]JENW18--
S0M,W=CQG@]:F\$8I=88\$F*|.)(IC%P M!&Z:_ 'CF5A>-,%/09?\ \$X!@LI3 IEN B PY!+Y.%#QH-
MJGG>?,DWYT&WQWP ((S!3U/EOZ